RxDoctor Payments Data

Harvind Chahal, MD

Dermatology · Oakland, CANPI 1508392168

Payments from drug & device makers

$8,656in general payments, 2019–2025

Across 263 payments — averaging $32.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • Incyte Corporation$752
  • Johnson & Johnson$586
  • Lilly USA, LLC$577
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$8,38097%
  • Education$2763%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,656 in reported general payments places this provider in the 75th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$292,137
Medicare patients
745
Services billed
2,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast16$49,862
Dupixent SyringeDupilumab12$49,289
Dupixent PenDupilumab13$49,267
Clobetasol Propionate154$5,418
Tacrolimus44$4,636
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc67$2,966
Triamcinolone Acetonide128$1,642
Metronidazole21$1,505
Doxycycline Hyclate22$1,329
Ketoconazole75$1,165
Fluocinonide21$831
Minoxidil25$403
Mupirocin23$301
Hydrocortisone56$265
ValacyclovirValacyclovir Hcl15$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$28$49,86216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,875 dermatology providers in California.

Other dermatology in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →